MAKING HEARING A PRIORITY
CILcare is dedicated to harnessing its unique expertise in Auditory Sciences to enable the early and specific detection of neurocognitive disorders and the treatment of associated auditory diseases.
Discover our pipeline
Looking for top-hit otoprotective compounds in your library?
Discover our fast and high-throughput in vitro screening assay to initiate your program in hearing disorders!
MAKING HEARING A PRIORITY
CILcare is a unique smart R&D platform committed to making hearing a priority. Take an in-depth look at how we can support your R&D program to prevent and treat ear disorders.
Discover our services
What can you do to prevent drug-induced hearing loss ?
Learn how to insulate your development program from ototoxicity
Watch the full video
CILcare won FACCNE’s 2023 Women in Business award!
CILcare’s team is honored to have been awarded by the French-American Chamber of New England (FACCNE) in the Women in Business category. The French-American Business Awards took place during FACCNE's annual gala, which has been celebrating for over 20 years the best...
CILcare announces the launch of the OrgaEar project with SATT AxLR and the University of Montpellier
Sylvie PUCHEU, CILcare’s Chief Scientific Officer and Philippe NERIN, SATT AxLR’s PresidentMontpellier - France – May 17th, 2023 – CILcare, a company specialized in the research and development of new therapies for auditory pathologies, and SATT AxLR are launching the...
CILCARE NOMINATED BY FACCNE FOR WOMEN IN BUSINESS AWARD 2023 !
CILcare’s team is honored and delighted to be part of the nominees for Women in Business Award by the French-American Chamber of New England (FACCNE). In one night only, FACCNE groups its Annual Gala and Awards Ceremony to recognize Excellence, Innovation and...
CILcare, a catalyzer for therapeutic development in auditory-related disorders
CILcare is a biotech company dedicated to harnessing its unique expertise in auditory sciences to enable the early and specific detection of neurocognitive and inflammatory diseases. CILcare’s proprietary pipeline focuses on synaptopathy, a disease affecting cochlear synapses and nerve fibers. Cochlear synaptopathy is clinically characterized by a lack of intelligibility in noisy environments, considered as the early signs of age-related hearing loss and aggravated by noise exposure.
Committed to its mission of accelerating the development of novel therapies for ear disorders, CILcare has built a unique smart R&D platform to offer external innovation to its partners. Based on an unmatched expertise in preclinical otology, CILcare has supported, worldwide, top hearing research companies, biotech, pharma and academic institutions in their various development stages.
With hearing labs established in Montpellier, France, and Lexington, MA, in partnership with CBSET, a biomedical translational research center, CILcare provides comprehensive preclinical programs including: drug screening on otic cell lines, cochlear explants studies, GLP-ototoxicity, inner ear pharmacokinetics, histology of the cochlea and vestibular systems, intra-cochlear deliveries, micro-surgery, micro-pump implantation, noise-induced, drug-induced, age-related, disease-related efficacy models in mice, rats, guinea pigs, tolerance and ototoxicity with state-of-the art auditory assessment with electrophysiology, electroacoustics and behavioral tests, gene transduction in the inner ear, transtympanic injections, cell grafts, …
“We relied on the expertise of CILcare for some of our studies on the neural basis of cochlear implant use (Glennon et al. Nature 2023). The services CILcare provided enabled us to confirm that our procedures were accurate and appropriate, and the cochleogram data and analysis from CILcare were of the highest quality. I’m grateful for the diligence and timely services they provided and will definitely work with CILcare again.” Robert Froemke, PhD, Professor, Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health
“Autifony has a strong interest in the discovery of new pharmaceutical treatments for hearing disorders, and has unique experience in the preclinical and clinical development of novel treatments for these indications. We recognise CILcare’s experience in the design and execution of preclinical studies in models of hearing loss. I personally had a great experience working with Aurore; she was very professional and friendly, and she was always available, which helped us to keep within timelines. I was impressed with the overall excellence of the whole team, and would strongly recommend them as a partner.” Nadia Pilati, Ph.D. Senior Electrophysiologist, Autifony Therapeutics Ltd
“CILcare is definitely more than a simple CRO! Following our work experience in PK/PD studies, CILcare now resonates as a trusted partner, fully committed to the success of their Sponsor’s assets. CILcare’s scientific expertise in the auditory system and neurosciences is no longer in doubt. The robustness of CILcare’s animal models, which highly mimic human ear disorders, gives us the confidence for translational success in clinical phases. It is always a pleasure to work with all the team members, they are very proactive, responsive, and dedicated to their customers.” Carmen Herrero, CSO, Spiral Therapeutics
“CILcare not only enabled us to access high quality specialised auditory pharmacokinetic and efficacy studies with high technical excellence whilst maintaining excellent care and attention to detail and animal welfare, but we also found their scientists not only insightful but also highly collaborative. The CILcare team were flexible and open to changes in protocol as the data from our studies developed and responded positively to time critical activities in highly professional manner. Without access to the studies undertaken at CILcare we would not discovered the novel scientific findings or the opportunity presented by the data from the studies undertaken.“ Senior Director, Future Pipeline Discovery, a Top ten pharmaceutical company
“CILcare played an indispensable role in achieving our goals for our preclinical R&D program. The gifted team members had good communications with us and have proven their highly-valued capability in the execution of ambitious studies by resolving various unexpected challenges. Their expertise and unique technical know-how in otology research enabled us to acquire valuable data to proceed with our program. I would like to thank the entire team for their warm hospitality and the in-depth introduction of their facilities in Montpellier. CILcare is for us a great partner, which I would recommend to any life science players aiming to create new and reliable drugs to treat ear disorders.” Hiroshi Uchino Ph.D, Senior Researcher, Astellas Pharma Inc.
Pharma / Biotech
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.